An update from TherapeuticsMD ( (TXMD) ) is now available.
TherapeuticsMD, Inc. reported a reduced net loss for Q3 2024, with operating expenses also declining due to its shift to a royalty-based business model. The company is exploring strategic alternatives, including potential mergers or acquisitions, but has not committed to any specific actions. Their cash reserves stand at $5 million, as they continue to focus on maximizing shareholder value amid a volatile stock environment.
See more data about TXMD stock on TipRanks’ Stock Analysis page.
